|
| Press Releases |
|
 |
|
| Tuesday, May 16, 2023 |
|
|
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology in the brain. more info >> |
|
| Monday, May 8, 2023 |
|
|
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration |
| Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an antibody-drug conjugate (ADC) with option rights for a strategic collaboration. more info >> |
|
|
エーザイ、抗体薬物複合体BB-1701について、BlissBioと戦略的提携に向けたオプション権を有する共同開発契約を締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗体薬物複合体（Antibody-Drug Conjugate：ADC）である BB-1701 について、Bliss Biopharmaceutical(Hangzhou) Co., Ltd.（本社：中国浙江省、以下 BlissBio）と戦略的提携に向けたオプション権を有する共同開発契約を締結したことをお知らせします。 more info >> |
|
| Thursday, April 6, 2023 |
|
|
Eisai Completes a Major Renovation of Tsukuba Research Laboratories |
| Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Eisai's medium-term business plan "EWAY Future & Beyond". more info >> |
|
|
エーザイ、筑波研究所の大規模改修工事が竣工 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、当社の中期経営計画 EWAY Future & Beyond における戦略投資の一環として実施した筑波研究所（茨城県）の大規模改修工事が竣工したことをお知らせします。 more info >> |
|
| Tuesday, April 4, 2023 |
|
|
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) using simulation modeling was published in the peer-reviewed journal Neurology and Therapy. more info >> |
|
|
エーザイ、臨床第III相Clarity AD試験データを用いた「レカネマブ」の長期的健康アウトカムについて、シミュレーションを用いた評価結果が査読学術専門誌Neurology and Therapy誌に掲載 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、アルツハイマー病（AD）による軽度認知障害（MCI）および軽度AD（総称して早期ADと定義）当事者様に対する抗アミロイドβ（Aβ）プロトフィブリル*抗体レカネマブ（一般名、米国ブランド名「LEQEMBITM」）の長期的な健康アウトカムへの影響をシミュレーション評価した結果が、査読学術専門誌Neurology and Therapy別ウィンドウで開きます誌に掲載されたことをお知らせします。 more info >> |
|
| Monday, April 3, 2023 |
|
|
Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System |
| Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name "Tazverik Tablets 200 mg", "tazemetostat") based on "Patient-Proposed Healthcare Services" system. more info >> |
|
|
エーザイ、抗がん剤タゼメトスタットについて、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を国立がん研究センターと締結 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、EZH2 阻害剤タゼメトスタット臭化水素酸塩（一般名、製品名：「タズベリク(R)錠 200mg」、以下 タゼメトスタット）について、国立研究開発法人国立がん研究センターと、「患者申出療養」制度に基づく医師主導臨床研究への協力に関する契約を締結したことをお知らせします。本臨床研究は、国立がん研究センター中央病院によって実施されます。 more info >> |
|
| Friday, March 31, 2023 |
|
|
Eisai Presented New Analyses of Aria and QOL on Lecanemab in Clarity AD at the AD/PD 2023 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Masverse Unveils Groundbreaking Blockchain Platform
Apr 27, 2024 02:40 HKT/SGT
|
|
|
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans
Apr 26, 2024 23:00 HKT/SGT
|
|
|
Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family
Apr 26, 2024 22:25 HKT/SGT
|
|
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 26, 2024 21:10 HKT/SGT
|
|
|
汇聚科技有限公司公布截至二零二三年十二月三十一日止末期业绩
Apr 26, 2024 18:53 HKT/SGT
|
|
|
匯聚科技有限公司公佈截至二零二三年十二月三十一日止末期業績
Apr 26, 2024 18:43 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 18:30: JST
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023
Apr 26, 2024 18:26 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 17:30 HKT/SGT
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
可持续发展三大支柱引领 海通恒信ESG必答卷高分亮相
Apr 26, 2024 15:28 HKT/SGT
|
|
|
可持續發展三大支柱引領 海通恆信ESG必答卷高分亮相
Apr 26, 2024 15:25 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 14:34: JST
|
|
|
スパークス・グループによる「宇宙フロンティア2号ファンド」の設立について
Apr 26, 2024 14:00: JST
|
|
|
中滙集團公佈2024財年中期業績
Apr 26, 2024 13:51 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
